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A B S T R A C T
According to the new EU Medical Devices (MDR) legislation coming into eﬀect in 2017, manufactures will have
to comply with higher standards of quality and safety for medical devices in order to meet common safety
concerns regarding such products. Metal alloys are extensively used in dentistry and medicine (e.g. orthopedic
surgery and cardiology) even though clinical experience suggests that many metals are sensitizers.
The aim of this study was to further test the applicability domain of the in vitro reconstructed human epi-
dermis (RhE) IL-18 assay developed to identify contact allergens and in doing so: i) determine whether diﬀerent
metal salts, representing leachables from metal alloys used in medical devices, could be correctly labelled and
classiﬁed; and ii) assess the ability of diﬀerent salts for the same metal to penetrate the skin stratum corneum.
Twenty eight chemicals including 15 metal salts were topically exposed to RhE. Nickel, chrome, gold, palladium
were each tested in two diﬀerent salt forms, and titanium in 4 diﬀerent salt forms. Metal salts were labelled
(YES/NO) as sensitizer if a threshold of more than 5 fold IL18 release was reached. The in vitro estimation of
expected sensitization induction level (potency) was assessed by interpolating in vitro EC50 and IL-18 SI2 with
LLNA EC3 and human NOEL values from standard reference curves generated using DNCB (extreme) and
benzocaine (weak). Metal salts, in contrast to other chemical sensitizers and with the exception of potassium
dichromate (VI) and cobalt (II) chloride, were not identiﬁed as contact allergens since they only induced a small
or no increase in IL-18 production. This ﬁnding was not related to a lack of stratum corneum skin penetration
since EC50 values (decrease in metabolic activity; MTT assay) were obtained after topical RhE exposure to 8 of
the 15 metal salts. For nickel, gold and palladium salts, diﬀerences in EC50 values between two salts for the same
metal could not be attributed to diﬀerences in molarity or valency. For chrome salts the diﬀerence in EC50
values may be explained by diﬀerent valencies (VI vs. III), but not by molarity. In general, metal salts were
classiﬁed as weaker sensitizers than was indicated from in vivo LLNA EC3 and NOEL data. Our in vitro results
show that metals are problematic chemicals to test, in line with the limited number of standardized human and
animal studies, which are not currently considered adequate to predict systemic hypersensitivity or auto-
immunity, and despite clinical experience, which clearly shows that many metals are indeed a risk to human
health.
1. Introduction
Metals have been extensively used in medical devices for many
years, in particular in dentistry and orthopedic surgery. Furthermore,
metals are generously incorporated into jewelry and many consumer
products e.g. sunscreens, food, paint. According to the new EU Medical
Devices (MDR) legislation coming into eﬀect in 2017, manufactures
will have to comply with higher standards of quality and safety for
medical devices in order to meet common safety concerns regarding
such products. The current recommendations for testing of almost all
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medical devices for cytotoxicity, irritation and sensitization are de-
scribed in ISO 10993-1 which describes how to set up a testing strategy
for the safety evaluation of medical devices. In particular, ISO 10993-10
describes tests for irritation and sensitization. With regards to testing
sensitization potential of metal salts derived from medical devices, data
from animal or human studies performed under standardized condi-
tions is limited. Metals are problematic chemicals to test in the mouse
local lymph node assay (LLNA) and in human studies using eg: DSA05,
NOEL, LOEL (see ICCVAM database (Basketter et al., 2014; Gerberick
et al., 2005; Iccvam, 2011a,b) as ionization followed by binding to a
hapten is a primary condition for activation of the human immune
system. The correct labeling (sensitizer or not) and classiﬁcation (po-
tency) of a chemical is important in order to determine the maximum
safe concentration for human exposure and to decide whether a less
potent sensitizer can replace a more potent sensitizer without eﬀecting
the function of the metal alloy.
Despite the lack of robust data from animal and human studies,
clinical experience does indicate that a number of metals may be con-
tact sensitizers and may elicit a type IV delayed hypersensitivity reac-
tion in the form of allergic contact dermatitis. Even though metal al-
lergy prevalence in large cohorts is generally unknown (Schedle et al.,
2007), there are estimates that up to 17% of women and 3% of men
have allergies to nickel and that 1–3% are allergic to cobalt and chro-
mium (Thyssen and Menne, 2010). Mercury, gold and palladium are
typical metals used in dentistry that have also been indicated as contact
sensitizers with palladium cross reacting with nickel (Gawkrodger,
2005; Muris et al., 2012). Furthermore, rare adverse reactions to tita-
nium containing implants suggests that titanium may also be a sensi-
tizing metal (Wood and Warshaw, 2015; Fage et al., 2016). Testing of
potential sensitizers and clinical diagnostic testing for suspected contact
allergy is traditionally carried out by applying the metal test chemical
in the form of a salt to the skin of an animal of human under standar-
dized conditions. Preferably the salt should dissolve to form metal ions.
Metal salts representative of leachables detected in blood and urine are
used to apply the ionized metal to the skin of the mouse or human.
However, it is generally not taken into account that a number of dif-
ferent salts exist for each metal with diﬀerent solubility, stratum cor-
neum penetration and cytotoxic/irritant properties which may ser-
iously confound the interpretation of the test results by giving false
negative outcomes and under-estimations
Over the last few years, considerable energy has been invested in
developing human in vitro methods to identify contact sensitizers. A
number of these alternative test methods, e.g. DPRA (OECD-TG 442C),
KeratinoSens™ (OECD-TG 442D) and h-CLAT, when incorporated into
an Integrated Testing Strategy, are now able to replace animal models
such as LLNA for hazard identiﬁcation (Rovida et al., 2015; Strickland
et al., 2016). During the Sens-it-iv Framework 6 project, we developed a
reconstructed human epidermis (RhE) in vitro assay for not just iden-
tifying contact sensitizers but also for assessing sensitizer potency
(Gibbs et al., 2013). RhE consist of proliferating and diﬀerentiating
keratinocytes grown at the air-liquid interface. Since RhE are cultured
exposed to the air, complete epidermal diﬀerentiation takes place with
the formation of a stratum corneum thus enabling topical chemical
application to take place in a similar manner to animal or human
testing under standardized conditions. Keratinocytes play a key role in
sensitization and activation of the immune responses as described in the
Adverse Outcome Pathway for sensitization (Rovida et al., 2015). The
diﬀerentiated epidermis controls chemical bioavailability via the
stratum corneum and the underlying viable keratinocytes trigger, via
the inﬂammasome and NF-kB pathway, an inﬂammatory response in
the form of (pro-) inﬂammatory cytokine release (Martin, 2015a).
Among the many cytokines secreted by keratinocytes, IL-18 has been
shown to play a key role in induction of allergic contact dermatitis
(sensitization) by inﬂuencing the migration of Langerhans cells and
dendritic cells to the draining lymph nodes, and in turn the presentation
of the haptenized proteins to T cells (Antonopoulos et al., 2008;
Okamura et al., 1995). IL-18 has no apparent role in irritant contact
dermatitis, indicating that the role of IL-18 in contact hypersensitivity is
not simply part of a general requirement for IL-18 in skin inﬂammation
(Antonopoulos et al., 2008). IL-18 plays a pivotal role in sensitization
since it promotes a Th1- type immune response by enhancing the se-
cretion of pro-inﬂammatory mediators such as TNFα, CXCL8 and IFNγ
(Okamura et al., 1995; Cumberbatch et al., 2001). Importantly, we have
shown that IL-18 can now be used to identify contact sensitizers from
respiratory sensitizers and non-sensitizers in an RhE in vitro assay
(Gibbs et al., 2013; Andres et al., 2017; Galbiati et al., 2017). The RhE
IL-18 assay could identify with 95% accuracy a panel of 17 contact
sensitizers. Potency assessment correlated better with human DSA05
data which assesses the induction dose per skin area that produces a
positive response in 5% of the tested population than with LLNA data
(Gibbs et al., 2013). The assay was extremely transferable from the in
house VUmc model to commercially available RhE (Gibbs et al., 2013;
Andres et al., 2017; Teunis et al., 2014). In the assay prediction model
(Gibbs et al., 2013), depending on the RhE used, a chemical is labelled
(YES/NO) as a sensitizer if, in 2 out of 3 independent runs, a threshold
of≥ 5 fold IL-18 release into the culture supernatant occurs in order to
avoid irritants scoring as false positive. Potency, on the other hand
which is related to the irritant potential of the chemical, is assessed by
the chemical concentration resulting in 50% decrease in cell viability
(EC50) or in 2 fold increase in IL-18 release (SI2). By deﬁnition
therefore, potency is related to the irritant potential of the chemical and
does not distinguish a sensitizer from a non-sensitizer: the stronger the
sensitizer the lower the EC50 or IL-18 SI2 value will be (Dos Santos
et al., 2011; Spiekstra et al., 2009). In line with this, the irritant ca-
pacity of chemicals has long been clinically recognized to represent an
additional risk factor for sensitization induction (Agner et al., 2002;
Basketter et al., 2007; Bonneville et al., 2007; Grabbe et al., 1996;
Mclelland et al., 1991).
In this study, we expand on our recently published study that de-
scribes the use of the RhE assay to estimate the expected sensitization
induction level by interpolating in vitro EC50 and IL-18 SI2 values to
predict LLNA EC3 and/or human NOEL from standard curves generated
using reference contact sensitizers (Galbiati et al., 2017). In order to
test the sensitizing potential of metal salts as replacement for metal ions
leaching from routinely used medical devices further, and to gain more
insight into the mechanism by which diﬀerent metal salts for the same
metal may inﬂuence the read out of the current skin patch test, we
tested a panel of 28 chemicals consisting of 17 metal salts, 8 non-metal
sensitizers and 4 non-sensitizers (including zinc chloride) in the RhE IL-
18 assay. For four metals (nickel, chrome, gold, palladium), the same
metal was tested in two diﬀerent salt forms, and titanium was tested in
4 diﬀerent salt forms to investigate the inﬂuence of molarity, valency
and cytotoxicity on the outcome of the assay.
2. Materials and methods
2.1. Reconstructed human epidermis
Healthy human neonatal foreskin was obtained after informed
consent from patients undergoing routine surgical procedures. Skin was
used anonymously and in accordance with the “Code for Proper Use of
Human Tissue” as formulated by the Dutch Federation of Medical
Scientiﬁc Societies (www.fmwv.nl), and following procedures approved
by the VU University medical center institutional review board.
VU University medical center in-house RhE (VUmc-RhE) were used
in this study. RhE were constructed from human foreskin keratinocytes
as described previously (Dos Santos et al., 2011; Spiekstra et al., 2009).
In short, keratinocytes (passage 2) were seeded into a 12 mm diameter
transwell (pore size of 0.4 mm; Corning, NY, USA) and grown sub-
merged in medium containing DMEM/Hams F12 (3:1), 1% ultroserG,
1 μM hydrocortisone, 1 μM isoproteronol, 0.1 μM insulin and 1 ng/mL
KGF for 1 week. Cultures were then lifted to the air–liquid interface and
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cultured for 4 days in keratinocyte culture medium (DMEM/Hams F12
(3:1), 0.2% ultroser G, 1 μM hydrocortisone, 1 μM isoproterenol, 0.1
μM insulin, 1.0 × 10−5 M l-carnitine, 1.0 × 10−2 M l-serine, and 2 ng/
mL KGF). After another 4 days, 50 μg/mL ascorbic acid was added and
RhE were cultured for an additional 10 days. Unless otherwise stated,
all additives were purchased from Sigma (St. Louis, MO). RhE were
incubated at 37 °C, 7.5% CO2 and medium was refreshed twice a week.
2.2. Chemicals and chemical exposure
A total of 28 chemicals were tested (Table 1). Non-metal chemicals
were selected from the ICCVAM data base and consisted of 8 sensitizers
of diﬀerent potencies (extreme, strong, moderate, weak) and 3 non-
sensitizers. To further explore the applicability domain of the RhE po-
tency assay for testing metals used in medical devices, 5 metal sensi-
tizers, 1 metal non-sensitizer and 2 non-classiﬁed metal sensitizers were
studied. Furthermore 2 diﬀerent metal salts were tested for chrome,
nickel, gold and palladium, and 4 diﬀerent metal salts were tested for
titanium. RhE were topically exposed to chemicals as previously de-
scribed (Gibbs et al., 2013). In brief, chemicals were dissolved in either
acetone olive oil (AOO 4:1) or water. Finn Chamber patch test ﬁlter
paper discs 11 mm (Epitest LTD Oy, Finland) were impregnated with
35 μl of the chemical or vehicle (control) and applied topically to the
RhE stratum corneum for 24 h. This method of application closely mi-
mics diagnostic chemical administration during patch testing of pa-
tients with suspected allergy in our out-patient clinic. Chemical ex-
posures were performed using a single dose response with 2-fold serial
dilutions starting from 200 mg/ml or the maximum soluble con-
centration. After chemical exposure, ﬁlter paper discs were removed.
Metabolic activity was determined by MTT assay and culture super-
natants were stored at −20 °C for analysis by ELISA.
2.3. Determination of RhE viability
The MTT assay measures mitochondrial activity, which is re-
presentative of cell viability. The MTT analysis was performed in 12-
well plates, exactly as described in detail previously (Gibbs et al.,
2013). In short, RhE were placed on top of 0.5 ml MTT (Sigma) dis-
solved in PBS (5 mg/ml) in a 12 well plate for 2–3 h. RhE were then
transferred to a new 12-well plate and incubated overnight in the dark,
at room temperature with 0.5 ml isopropanol (Merck). Next day, ab-
sorbance was measured at 570 nm with a Mithras LB 940 spectro-
photometer. Results are expressed relative to vehicle.
2.4. Determination of IL-18 production
The amount of IL-18 present in culture supernatants was quantiﬁed
using a commercially available sandwich ELISA according to the sup-
plier's instructions (MBL, Nagoya, Japan) and exactly as described
previously (Gibbs et al., 2013). Results are calculated in pg/mL from a
standard curve and then converted to a Stimulation Index (SI) com-
pared to vehicle exposed RhE.
2.5. Determination of interference of chemical with MTT assay or IL-18
ELISA
Chemicals which interfere with the readout of the MTT assay or IL-
18 were excluded since they fall outside of the applicability domain of
the assay.
MTT assay: the highest soluble chemical concentration was tested in
the absence of RhE. If a colour change was observed then the chemical
was excluded. In this way, calcium titanate was excluded from MTT/
viability analysis.
IL-18 ELISA: a known amount of human recombinant IL-18 (500 pg/
ml) was used to spike directly culture supernatant from RhE exposed to
200 mg/ml of the metals (the highest salt concentration used in the
assay). If the salt penetrated the RhE reaching the culture supernatant
and interfered with the IL-18 ELISA then the calculated IL-18 value
obtained from the ELISA would diﬀer from the spiked 500 pg/ml value
indicating that the metal interfered with the ELISA and had to be ex-
cluded. None of the tested metals interfered with the ELISA and
therefore all data was included.
2.6. Data analysis and prediction model
Data analysis and prediction model were performed according to
SOP (Gibbs et al., 2013; Teunis et al., 2014). Diﬀerent RhE batches were
used in each experimental run. Data represent at least two independent
experiments. As results are incorporated into prediction models it is not
feasible nor necessary to run statistics on each experiment. The fol-
lowing readouts were used:
• Sensitizer prediction model (YES/NO): Chemicals were labelled as
sensitizers according to the prediction model described previously
which avoids irritants scoring as false positives: if 2/3 independent
runs results in≥ 5 fold increase in IL-18 secretion at RhE viabi-
lity≤ 40% (60% cytotoxicity) compared to vehicle then the che-
mical scores as a sensitizer (H317) (Gibbs et al., 2013). (Cytotoxi-
city/membrane permeability is required in order to release
intracellular IL-18 into the culture supernatant, thus making it not
necessary to perform an additional tissue dissociation and extraction
step). Note, the chemical concentration which results in≥ 5 fold
increase in IL-18 secretion may be diﬀerent between runs due to
batch and donor variation in response to the chemical.
• Sensitizer potency assessment, which correlates to irritant potential
Table 1
test chemicals and vehicles.
Chemical CAS# Vehicle
Non-metal
sensitizers
Chemical tested
Dinitrochlorobenzene 97−00-7 AOO
4-nitrobenzylbromide 100−11-8 AOO
Methyldibromo glutaronitrile 3591−65-7 AOO
Cinnamaldehyde 104−55-2 AOO
Resorcinol 108−46-3 AOO
Eugenol 97−53-0 AOO
Isoeugenol 97−54-1 AOO
Benzocaine 94−09-7 AOO
Metal sensitizers
Chrome Potassium dichromate (VI) 7778−50-9 Water
Chromium (III) chloride 10025−73-7 Water
Nickel Nickel (II) chloride hexahydrate 7791−20-0 Water
Nickel (II) sulfate hexahydrate 10101−97-0 Water
Gold Gold (I) chloride 10294−29-8 Water
Sodium aurothiosulfate (I) 18497−75-1 Water
Cobalt Cobalt (II) chloride 7646−79-9 Water
Mercury Mercuric (II) chloride 7487−94-7 Water
Copper Copper (II) sulfate 7758−98-7 Water
Unclassiﬁed metals
Palladium Sodium tetrachloropalladate (II) 13820−53-6 Water
Palladium (II) chloride 7647−10-1 Water
Titanium Titanium (IV) isopropoxide 546−68-9 AOO
Titanium (IV) bis (ammonium
lactato) dihydroxide solution
65104−06-5 Water
Titanium (IV) oxide 13463−67-7 AOO
Calcium titanate 12049−50-2 AOO
Non-sensitizers Sodium dodecyl sulfate 151−21-3 Water
Lactic Acid 50−21-5 Water
Salicylic Acid 69−72-7 Water
Zinc Zinc (II) chloride 7646−85-7 Water
The vehicles used in this study for dissolving chemicals before applying topically to RhE.
AOO = acetone: olive oil (4:1); Water was distilled. Chemical suppliers were Sigma-
Aldrich.
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of the chemical: i) EC50 value is the chemical concentration re-
quired to reduce metabolic activity (corresponding to cell viability)
to 50% of the value obtained by the vehicle (water or acetone/olive
oil 4:1). Values were obtained by linear regression analysis based on
changes in metabolic activity (MTT). ii) IL-18 SI2 values were ob-
tained by linear regression analysis based on the chemical
Fig. 1. Dose response eﬀects of non metal sensitizers and non sensitizers on IL-
18 release and cell viability in the VUmc in house RhE model. RhE were exposed
to chemicals as described in Materials and Methods and Table 1. IL-18 (ﬁlled
bars) was assessed by ELISA and results are expressed as stimulation index (SI)
compared to vehicle alone. Cell viability (open bars) was assessed by MTT re-
duction assay and is expressed relative to vehicle. Results are expressed as
average ± SD of 3 independent runs. Both dotted line = 60% viability cut-oﬀ
and dashed line = IL-18 SI5 cut-oﬀ are used in the chemical labeling (YES/NO)
prediction model shown in Table 2 and described in Materials and Methods,
section 2.6. Chemical classiﬁcation is derived from Tables 1 and 3.
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concentration resulting in a 2 fold release of IL-18 into culture su-
pernatants.
Interpolation prediction model: LLNA EC3 (%) and NOEL (μg/mL)
were predicted from in vitro EC50 and IL-18 SI2 values using the slope
of the standard curve obtained from reference chemicals DNCB
(Basketter et al., 1997) and benzocaine (Van Och et al., 2000) and the
following equation: Y = slope x X + intercept where Y = predicted in
vivo value and X = in vitro EC50 or IL-18 SI2 value.
A binary prediction model was used in which EC50 or IL-18
SI2≥ 0.7% = weak to moderate sensitizer and EC50 or IL-18
SI2 < 0.7%= strong to extreme sensitizer. Note, potency assessment
does not distinguish a sensitizer from a non sensitizer since i) EC50
value is related to the irritant/cytotoxic potential of the chemical and
ii) IL-18 SI2 value is below the threshold for labeling a chemical.
Statistical analysis was performed using GraphPad Prism version
6.00 for Windows (GraphPad Software, San Diego, CA, USA) and
Microsoft excel.
3. Results
3.1. Chemical labeling (YES/NO)
Non-metal chemicals: dose response results used in the prediction
model for the 8 non-metal sensitizers and 4 non-sensitizers are shown in
Fig. 1 and values obtained for the 3 independent runs are shown in
Table 2. All chemicals resulted in a dose dependent decrease in RhE
viability within the range of≤ EC40 thus enabling the YES/NO IL-18
SI5 prediction model to be implemented as previously described (Gibbs
et al., 2013). Of the 8 non-metal sensitizers tested, 6 correctly scored as
sensitizers showing a good correlation with the VUmc RhE and com-
mercially available epiCS and EpiDerm models (Gibbs et al., 2013;
Galbiati et al., 2017). Methyldibromo glutaronitrile and resorcinol,
both chemicals not tested in the RhE assay before, scored false nega-
tively as non-sensitizers. All 4 non-sensitizers were scored correctly,
including the metal zinc chloride.
3.1.1. Metal sensitizers
With regards to RhE viability, 6 of the 14 metal salts did not result
in a decrease in RhE viability≤ 40% compared to vehicle exposed
cultures and therefore did not fulﬁl the requirements for the prediction
model (Fig. 2; Table 2). Calcium titanate interfered with the MTT assay
and therefore was also excluded from the viability analyses. Therefore,
a total of 7 metal salts could not be labelled since it was questionable
whether they penetrated the stratum corneum and also cytotoxicity/
membrane porosity is required for the release of intracellular IL-18 into
culture supernatants. Indeed, the IL-18 SI5 was not reached for these 7
metals. Of the 8 remaining metal salts which did fulﬁl the requirements
for the prediction model, very surprisingly only 2 resulted in≥ 5 fold
increase in IL-18 in 2/3 independent runs, thus scoring positive as
sensitizers (Table 2). These metals were cobalt (II) chloride (run 1:
25 mg/ml, IL-18 SI = 5.63; run 2: 100 mg/ml, IL-18 SI = 8.6; run 3:
6.25 mg/ml, Il-18 SI = 6.38) and potassium dichromate (VI) (run 1:
12.5 mg/ml, IL-18 SI = 10.9; run 2: 12.5 mg/ml, IL-18 SI = 9.56; run
Table 2
Prediction model for chemical labeling.
Chemical IL-18 SI≥ 5 at≤ EC40 Positive repetitions Classiﬁcation
Repetition 1 Repetition 2 Repetition 3
Non-metal sensitizers
Dinitrochlorobenzene 10.2 28.27 22.41 3/3 Sensitizer
4-Nitrobenzylbromide 17.47 1.79 13.01 2/3 Sensitizer
Methyldibromo gluaronitrile 2.79 3.58 1.52 0/3 Non Sensitizer
Cinnamaldehyde 12.55 6.02 22.81 3/3 Sensitizer
Resorcinol 2.56 8.3 0.04 1/3 Non Sensitizer
Eugenol 12.25 15.95 4.28 2/3 Sensitizer
Isoeugenol 9.74 11.25 8.83 3/3 Sensitizer
Benzocaine 3.32 9.76 6.10 2/3 Sensitizer
Metal sensitizers
Chrome Potassium dichromate (VI) 10.9 9.56 6.67 3/3 Sensitizer
Chromium (III) chloride 1.63 – 1.39 0/3 Non Sensitizer
Nickel Nickel (II) chloride hexahydrate 2.98 3.39 4.61 0/3 Non Sensitizer
Nickel (II) sulfate hexahydrate – – – 0/3 Non Sensitizer
Gold Gold (I) chloride 0.25 1.76 – 0/3 Non Sensitizer
Sodium aurothiosulfate (I) – – – 0/3 Non Sensitizer
Cobalt Cobalt (II) chloride 5.63 8.6 6.38 3/3 Sensitizer
Mercury Mercuric (II) chloride – – – 0/3 Non Sensitizer
Copper Copper (II) sulfate – – nd 0/2 Non Sensitizer
Unclassiﬁed metals
Palladium Sodium tetrachloropalladate (II) – 1.31 1.29 0/3 Non Sensitizer
Palladium(II) chloride – – – 0/3 Non Sensitizer
Titanium Titanium (IV) isopropoxide – – – 0/3 Non Sensitizer
Titanium (IV) bis(ammonium lactato) dihydroxide solution – – – 0/3 Non Sensitizer
Titanium (IV) oxide – – – 0/3 Non Sensitizer
Calcium titanate nd nd nd 0/0 Not classiﬁed
Non-sensitizers
Zinc chloride (II) 0.15 0.45 0.18 0/3 Non Sensitizer
Sodium dodecyl sulfate 2.90 11.36 2.28 1/3 Non Sensitizer
Lactic Acid 0.67 – 0.29 0/3 Non Sensitizer
Salicylic Acid 3.45 0.10 1.18 0/3 Non Sensitizer
The prediction model states that if 2/3 independent runs results in≥ 5 fold increase in IL-18 secretion at RhE viability≤ 40% compared to vehicle then the chemical scores as a
sensitizer. The maximum IL-18 SI observed in the dose response at a cell viability≤ 40% relative to the vehicle is shown. Note the chemical concentration at which the maximum IL-18 SI
occurs may diﬀer between independent runs due to batch and donor variation in RhE (see detailed prediction model in Materials and Methods). Chemical concentrations in the dose
response were 2 fold serial dilutions with highest concentration being 200 mg/ml (see Fig. 1). Correctly labelled chemicals are shown bold underlined.
(−) No values obtained at cell viability≤ 40% relative to the vehicle and/or IL-18 was below the detection limit of the ELISA. (nd) Not done.
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3: 12.5 mg/ml, Il-18 SI = 6.67). Of note, chemical concentrations re-
sulting in maximum IL-18 SI may diﬀer between runs due to RhE batch
and donor variation, and explains why the average of the values ob-
tained for Cobalt (II) chloride in the 3 independent runs, when taken
together, falls below SI5 as observed in Fig. 2. Notably, the other
chrome salt tested in the assay, chromium (III) chloride, scored nega-
tive even though RhE viability decreased to≤ 40%. In summary, with
the exception of cobalt (II) chloride and potassium dichromate (VI), IL-
18 was detected consistently at low levels (no SI5 reached) in RhE
culture supernatants exposed to metals resulting in a consistent nega-
tive score as non-sensitizer or not labelled (0/3 positive repetitions;
Table 2).
Since very few metals resulted in an IL-18 SI5 from RhE required to
give a label (YES/NO), it was next determined whether metal exposure
could result in an IL-18 SI2 from RhE since this would enable sensitizer
potency to be determined even if the label could not be established for
metals in this assay (Gibbs et al., 2013). Note, an IL-18 SI2 in the VUmc
RhE model will not distinguish a sensitizer for an irritant as this low
threshold will result in false positives in line with sensitizer potency
correlating to irritant potential of a chemical. For the non-metal sen-
sitizers, all 8 chemicals resulted in an IL-18 SI2 in line with our previous
publication. For the metals, only 5/16 metals salts (including zinc
chloride) resulted in an IL-18 SI2 value in at least 2/3 runs.
3.2. Determination of chemical concentration which results in 50% decrease
in RhE viability (EC50 value)
Previously we have shown that non-metal sensitizer potency could
be accurately determined from the EC50 value obtained after chemical
exposure (Gibbs et al., 2013; Teunis et al., 2014). For all 11 non-metal
chemicals (sensitizers and non-sensitizers), an EC50 value could be
obtained (Table 3). However, with regards to the metals, an EC50 value
could only be obtained for 9/16 metal salts (including the non-sensi-
tizer zinc chloride) (Fig. 2, Table 3). No EC50 value was obtained
within the tested range of< 200 mg/ml for nickel (II) sulfate hex-
ahydrate, sodium aurothiosulfate (I), palladium (II) chloride, or the
titanium salts.
3.3. Comparison of diﬀerent salts for same metal
When comparing salts for the same metal more closely it was ob-
served that potassium dichromate (VI) and nickel (II) chloride had a
lower EC50 and IL-18 SI2 than chrome (II) chloride and nickel (II)
sulfate respectively; and sodium tetrachloropalladate (II) and gold (I)
chloride had a lower EC50 value than their respective salts palladium
(II) chloride, sodium aurothiosulfate (I) (Table 3). For nickel, gold and
palladium, these diﬀerences could not be attributed to diﬀerences in
molarity or valency since both salts for the same metal were of the same
valency and one metal salt was clearly more cytotoxic than the other
metal salt at a lower (rather than higher) molarity (Fig. 2). For chrome
salts the diﬀerence may possibly be explained by the diﬀerent valancies
(VI vs. II), but not by molarity.
Fig. 2. Dose response eﬀects of metal sensitizers and unclassiﬁed metal salts on IL-18
release and cell viability in the VUmc in house RhE model. RhE were exposed to che-
micals as described in Materials and Methods and Table 1. IL-18 (ﬁlled bars) was assessed
by ELISA and results are expressed as stimulation index (SI) compared to vehicle alone.
Cell viability (open bars) was assessed by MTT reduction assay and is expressed relative to
vehicle. Results are expressed as average ± SD of 3 independent runs. Both dotted
line = 60% viability cut-oﬀ and dashed line = IL-18 SI5 cut-oﬀ are used in the chemical
labeling (YES/NO) prediction model shown in Table 2 and described in Materials and
Methods, section 2.6. Chemical classiﬁcation is derived from Tables 1 and 3.
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3.4. Chemical potency: prediction of human NOEL and LLNA EC3 from in
vitro EC50 value and IL-18 SI2 values
Next the LLNA EC3 and human NOEL values were predicted with
the simple approach we recently described to estimate the in vivo
sensitization induction level (Gibbs et al., 2013; Galbiati et al., 2017).
Correlation curves were created with reference chemicals extreme
strong DNCB and weak benzocaine using in vivo and in vitro data
Table 3
Comparison of in vivo data with RhE EC50 and IL-18 SI2.
Chemical classiﬁcation
according to LLNA
Human
Category
scale
LLNA-EC3 (%) prediction Human NOEL (μg/cm2)
prediction
EE EC50 EE IL-18SI2
In vivo EC50 IL-18 In vivo EC50 IL-18 % μg/cm2 % μg/cm2
Extreme<0.1
Dinitrochlorobenzene 1 0.006–0.13 0.08 0.06 8.8 8.8 8.8 0.06 ± 0.001 27.6 ± 0.45 0.03 ± 0.007 13.4 ± 3.12
4-Nitrobenzylbromide ND 0.05 0.05 0.06 ND 8.8 8.8 0.05 ± 0.05 22.3 ± 22.3 0.03 ± 0.03 13.4 ± 13.4
Strong>0.1<1
Methyldibromo gluaronitrile 2 0.9 1.42 1.60 ND 131 149 0.54 ± 0.37 241 ± 165 0.21 ± 0.05 93.6 ± 23.3
Cinnamaldehyde 2 0.2–3.1 1.00 1.00 200, 400,
591+
93 94 0.39 ± 0.34 174 ± 152 0.14 ± 0.15 62.4 ± 66.9
Moderate>1<10
Isoeugenol 2 0.5–5.0 3.62 6.31 69, 250 330 576 1.32 ± 0.55 589 ± 245 0.76 ± 0.05 339 ± 22.3
Resorcinol 4 5.5–6.3 6.24 7.59 ND 568 693 2.25 ± 0.99 1003 ± 441 0.91 ± 1.27 406 ± 566
Moderate - Weak>1<100
Eugenol 3 4.9–40.9 2.52 2.45 1938,
3200
231 226 0.93 ± 0.70 415 ± 312 0.31 ± 0.20 138 ± 89.2
Benzocaine 4 18,22,37 22 22 2000 2000 2000 7.85 ± 3.27 3500 ± 1458 2.59 ± 1.38 1155 ± 615
Metal sensitizers
Extreme<0.1
Potassium dichromate (VI) 1 0.01–0.33 1.17 2.88 111 107 266 0.45 ± 0.38 199 ± 171 0.36 ± 0.34 161 ± 151
Mercuric (II) chloride 1 0.39 1.26 0.75 924 115 67 0.48 ± 0.05 214 ± 24.1 0.11 ± 0.08 46.8 ± 33.7
Strong>0.1<1
Gold (I) chloride 2 0.48 11.56 – 65 1053 – 4.15 ± 2.29 1850 ± 1022 NR NR
Cobalt (II) chloride 2 0.4–0.8 4.69 5.12 ND 428 477 1.70 ± 2.01 758 ± 896 0.63 ± 0.34 282 ± 152
Copper (II) sulfate ND 0.4# 4.2 – ND 389 – 1.55 ± 1.19 690 ± 532 NR NR
Moderate>1<10
Nickel (II) sulfate
hexahydrate
2 4.8–5.5 26.5 – ND 2409 – >20.0 >9000 NR NR
Nickel (II) chloride
hexahydrate
2 5.5 8.4 21.9 154 768 1991 3.03 ± 1.24 1352 ± 551 2.58 ± 1.21 1150 ± 539
Unclassiﬁed metal salts
Sodium aurothiosulfate (I) ND ND >55 – ND >500-
0
– >20.0 >9000 NR NR
Chromium (III) chloride ND ND 33 – ND 3057 – 11.99 ± 3.93 5344 ± 1754 NR NR
Sodium tetrachloropalladate
(II)
ND ND 8.58 – ND 780 – 3.08 ± 1.45 1374 ± 648 NR NR
Palladium (II) chloride ND ND >55 – ND >500-
0
– >20.0 >9000 NR NR
Titanium (IV) isopropoxide ND ND >55 18 ND >500-
0
1658 >20.0 >8917 2.15 ± 0.06 959 ± 25.0
Titanium (IV) bis(ammonium
lactato) dihydroxide
solution
ND ND >55 – ND >500-
0
– >20.0 >8917 NR NR
Titanium (IV) oxide ND ND >55 – ND >500-
0
– >20.0 >8917 NR NR
Calcium titanate ND ND – 17 ND – 1520 nd nd 1.97 ± 1.82 880 ± 811
Non sensitizers
Zinc chloride (II) 6$ NS NS$ 4.65 ± 2.5 2073 ± 1115 NR NR
Sodium dodecyl sulfate 6 NS NS 0.13 ± 0.06 58.0 ± 26.7 0.08 ± 0.04 35.7 ± 17.8
Lactic Acid 6 NS NS 6.76 ± 1.14 3014 ± 508 2.39 ± 0.76 1066 ± 339
Salicylic Acid 6 NS NS 1.06 ± 0.08 473 ± 35.7 NR NR
The LLNA EC3 values are expressed as % and relative potency classiﬁcation is reported. Potency classiﬁcation is based on the mathematical estimation of the EC3 value (%)> 10
to< 100 are classiﬁed as weak,> 1 to< 10 moderate,> 0.1 to< 1 strong,< 0.1 extreme. For LLNA in vivo data, a range of values is shown which was obtained from the ICCVAM
database and Gerberick et al., 2005 (2, 4).
Human Category Scale: 1 = Extensive evidence of contact allergy in relation to degree of exposure and size of exposed population; 2 = A frequent cause of contact allergy, but of less
signiﬁcance compared with induction of skin sensitization in a HRIPT category 1; 3 = A common cause of contact allergy, perhaps requiring higher exposure compared with category 2;
4 = Infrequent cause of contact allergy in relation to level of exposure; 5 = A rare cause of contact allergy except perhaps in special circumstances (1).
For NOEL in vivo data, references were obtained from Basketter et al., 2014 (1) and ICCVAM data base (4).
In vitro EC50 and IL-18 SI2 values are the arithmetic means obtained from at least 2 independent experiments, and were calculated from RhE exposed to the chemicals as described in the
Materials and Methods section. EC50 and IL-18 SI2 values were converted from mg/ml to % and μg/cm2 for comparisons with in vivo data. μg/cm2 conversion: μg = 35 μl chemical x μg/
1 μl; cm2 = pi x r2 = pi x 0.25 cm2 = 0.785 (example DNCB EC50 (0.62 × 35)/0.785 = 27.6 μg/cm2). These values are used to predict in vitro EC50 and IL-18 SI2 values correlating to
NOEL and LLNA-EC3 values using reference chemicals Benzocaine (29) and DNCB (28) and regression analysis derived from Figure 3.
ND indicates no data available; NS non-sensitizer; NR not reached in at least 2 runs; * cobalt sulfate data presented; $ zinc oxide data presented; #copper chloride presented.
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(Fig. 3; Table 3). The predicted LLNA EC3 (%) and NOEL (μg/cm2)
values of the remaining 26 chemicals were then calculated from the
linear regression curves using the corresponding EC50 and IL-18 SI2
values.
For the non metal sensitizers, the predicted LLNA EC3 and NOEL
values were very close to actual values. Only methyldibromo gluar-
onitrile fell slightly outside of its LLNA EC3 class but was within its
human NOEL class. Of note, methyldibromo gluaronitrile LLNA EC3
classiﬁcation was based on a single study reported in the literature (1).
Also, eugenol fell outside of its NOEL class by being predicted as a
stronger sensitizer than implied by actual NOEL data. However, it fell
correctly into the lower range of available LLNA EC3 data predicting it
as a moderate sensitizer. The human category score proposed by
(Basketter et al., 2014) also correlated well with the non metal LLNA
EC3, NOEL, EC50 and IL-18 SI2 data.
With regards to the metal salts, it should be emphasized that in vivo
data was extremely scarce and often a single value from a single study is
all that is reported (Table 3). In our study using the RhE prediction
model, in general the known metal sensitizing salts were predicted as
being weaker sensitizers than actual in vivo data indicated. Only pre-
dicted NOEL values for potassium dichromate correlated to actual va-
lues. Furthermore, all unclassiﬁed metal salts were predicted as extreme
weak contact sensitizers.
3.5. Chemical potency according to RhE EC50 value≥ 0.7% representing a
weak/moderate sensitizer and≤ 0.7% representing extreme/strong
sensitizer
Having observed that the metals predicted a lower LLNA EC3 and
NOEL potency than the actual in vivo values we next determined the
accuracy of predicting in vitro potency according to the prediction
model: RhE EC50 value≥ 0.7% representing a weak/moderate sensi-
tizer and≤ 0.7% representing extreme/strong sensitizer (Teunis et al.,
2014). Chromium (III) chloride, sodium aurothiosulfate (I), the palla-
dium salts and the titanium salts were not included in the following
analysis since no LLNA data was available. EC50 and IL-18 SI2 values
were obtained from 15 and 13 known sensitizing salts respectively and
showed an overall accuracy of 83% and 94% respectively with the
prediction model. With regards to the 8 non-metal sensitizers, the EC50
value had 100% accuracy and the IL-18 SI2 had 87.5% accuracy (out-
lier = eugenol) showing an extremely good correlation with LLNA
data. The metal sensitizers also showed good correlation with LLNA
data with EC50 and IL-18 SI-2 accuracy being 70% and 100% respec-
tively (outliers = gold (I) chloride, cobalt (II) chloride and copper (II)
sulfate). It was found that speciﬁcity (prediction of moderate/weak
sensitizers) was higher than sensitivity (prediction of extreme/strong
sensitizers) for the metal salts indicating again that metals, in general,
were predicted with lower potency in the human RhE assay than in
LLNA. The concordancy (same result scoring per chemical) between the
EC50 and IL-18 SI2 prediction models was 85%.
Next, we proceeded to predict the potency of the unclassiﬁed metal
salts (Table 4). Both palladium salts and all 4 titanium salts scored as
extreme weak sensitizers/irritants (no YES/NO label; see Table 2).
Furthermore, chromium (III) chloride and sodium aurothiosulphate (I),
chemicals for which no LLNA data was available, scored as moderate/
weak and extreme weak sensitizers respectively. Notably, when the
alternative salts for these two metals were analyzed it was found that
potassium dichromate (VI) scored as extreme/strong in line with LLNA
Fig. 3. Linear regression curves of RhE assay created with data from reference chemicals benzocaine and DNCB. Murine LLNA EC3 and human NOEL are plotted against in vitro RhE EC50
and IL-18 SI2 values using data for these 2 chemicals from Table 3. The regression curves were used to predict LLNA EC3 and NOEL (Y) values from in vitro (X) testing of chemicals shown
in Table 3 using the equation Y = slope x X – intercept (shown top left of each graph).
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data, whereas gold (I) chloride scored as a moderate/weak sensitizer in
contrast to LLNA data which scores gold as a strong sensitizer (data
from one LLNA study only, see Table 3).
4. Discussion
Metal alloys are extensively used in dentistry and orthopedic sur-
gery. This study had two aims: i) test the skin sensitizing potency of
metals used in medical devices; and ii) gain insight into how diﬀerent
metal salts may inﬂuence the readout of the diagnostic patch test assay.
Our results clearly show that metal ions entering the blood and urine
which form from metal ions leaching from routinely used in medical
devices are problematic chemicals to test in vitro, in line with the
limited number of standardized human and animal studies described in
the literature and despite clinical experience which clearly shows that
many metals are indeed a risk to human health. Currently used animal
models cannot reliably predict systemic hypersensitivity or auto-
immunity (Descotes, 2006). Where, with systemic hypersensitivity re-
actions, we refer to the immune-mediated reactions that involve the
entire body, and distinguish them from local (i.e. contact dermatitis)
reactions. In line with this it is important to remember that the RhE IL-
18 assay only identiﬁes a type IV hypersensitivity reaction and che-
micals triggering humoral hypersensitivity responses (types II and III)
are likely to be negative (Cumberbatch et al., 2001). Notably, metals
(nickel, cobalt, chromium, palladium, gold) have been reported to in-
duce a mixed Th1 and Th2-type cytokine response indicating that the
immunological mechanism involved is mixed and not a true type IV
response (Minang et al., 2006).
Skin irritation is the clinical result of an inﬂammatory response
resulting mainly from the release of pro-inﬂammatory cytokines from
epidermal cells (keratinocytes) in response to a chemical stimulus. The
pathophysiological changes associated with skin irritation include the
disruption of skin barrier, modiﬁcation of skin cells, cytokine release
and nerve ending changes. In order for a chemical to induce skin irri-
tation, the chemical must reach the viable epidermis, therefore, pene-
tration is needed. The in vitro skin irritation test using RhE is based
precisely on this mechanism: absorption and damage (cytotoxicity) of
keratinocytes, which parallel the release of pro-inﬂammatory mediators
(i.e. IL-1α) (see OECD test number 439). Intracellular accumulation of
IL-18 after classical sensitizer exposure is a result of neosynthesis of
pro-IL-18 via TLR activation and the NF-κB pathway followed by
posttranslational cleavage of pro IL-18 to IL-18 via the inﬂammasome
Table 4
Predictive capacity of RhE potency based on cut-oﬀ value for EC50 and/or IL-18 SI2 at< 0.7% for strong/extreme sensitizers and ≥ 0.7% for weak/moderate sensitizers.
EE-EC50 prediction IL-18 SI2 prediction
Reference result for chemical according to LLNA E/S<0.7 M/W≥ 0.7 E/S<0.7 M/W ≥ 0.7
9 strong/extreme chemicals 6 3 7 0
5 metals 2 3 3 0
4 non metals 4 0 4 0
5 weak/moderate chemicals 0 6 1 5
2 metals 0 2 0 2
3 non metals 0 4 1 3
total number of chemicals 15 13
metals 7 5
non metals 8 8
Sensitivity (%) 66.7 100
Metals only 40 100
non metals only 100 100
Speciﬁcity (%) 100 87.5
Metals only 100 100
non metals only 100 75
Accuracy (%) 83 93.7
Metals only 70 100
non metals only 100 87.5
Concordance between EC50 andIL-18 SI2 values 11 of 13 chemicals tested = 85 %
Metals only 4 of 5 chemicals tested = 80 %
non metals only 7 of 8 chemicals tested = 88 %
Prediction model for unclassiﬁed metal salts
Unclassiﬁed metal salts EE-EC50 % IL-18 SI2 % E/S<0.7 M/W≥ 0.7 LLNA EC3 prediction
Chromium (III) chloride > 20 NR No Yes Extreme weak
Sodium aurothiosulfate (I) 12 ± 4 NR No Yes Moderate/weak
Sodium tetrachloropalladate (II) 3.1 ± 1.5 NR No Yes Moderate/weak
Palladium (II) chloride > 20 NR No Yes Extreme weak
Titanium (IV) isopropoxide > 20 2.2 ± 0.6 No Yes Extreme weak
Titanium (IV) bis(ammonium lactato)
dihydroxide solution
> 20 NR No Yes Extreme weak
Titanium (IV) oxide > 20 NR No Yes Extreme weak
Calcium titanate nd 2.0 ± 1.8 No yes Moderate/weak
Data are based on results obtained for the total number of chemicals sensitizers tested from which an EC50 value (15 chemicals) or IL-18 SI2 value (13 chemicals) could be obtained (see
Table 3). No IL-18 SI2 value was obtained for gold (II) chloride or copper (II) sulfate and therefore the prediction model used 13 rather than 15 chemicals in the analysis.
E/S < 0.7 = extreme/strong sensitizer with EC50 cut-oﬀ value < 0.7 mg/ml M/W≥ 0.7 = moderate/weak sensitizer with EC50 cut-oﬀ value of ≥ 0.7mg/ml.
Sensitivity = percentage of correctly identiﬁed strong/extreme sensitizers; speciﬁcity = percentage of correctly identiﬁed weak/moderate sensitizers; accuracy = average of sensitivity
and speciﬁcity. Concordance is shown for 13 chemicals where both an EC50 value or IL-18 SI2 value was obtained. In brackets results are shown without inclusion of metals.
For the non labelled metals (no human NOEL, DSA05 or LLNAEC3 data available), potency prediction correlates to irritant or sensitizer potency. NR = IL-18 SI2 not reached in 2/3 runs.
EC50 > 20%= extreme weak.
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and caspase 1 (Martin, 2015a, 2015b; Galbiati et al., 2014). In our
assay, IL-18 is then released when the cell membrane becomes porous
due to cytotoxicity. Besides the low spontaneous release of IL-18
measurable in RhE, only contact sensitizers can induce IL-18 neo-
synthesis, above threshold levels indicating that the chemical must
reach the viable epidermis, otherwise the induction of IL-18 would not
be possible. Our results indicate that exposure to metal salts, in contrast
to other chemical sensitizers, only results in a small or no increase in IL-
18 production in RhE. This ﬁnding was not related to a lack of chemical
penetration since cytotoxicity (decrease in metabolic activity; MTT
assay) was observed after topical RhE exposure to 8 of the 15 metal
salts. Since most metal salts did result in some IL-18 production, the
pathways leading to IL-18 neo-synthesis and posttranslational cleavage
was not entirely obsolete. Also, even though we detected very low IL-18
release, it has recently been shown that nickel, cobalt and palladium
can bind directly to TLR4 resulting in dimerization and without prior
haptenization can trigger the secretion of inﬂammatory cytokines like
CXCL8 from dendritic cells. For gold the response can be attributed to
TLR3 binding (Rachmawati et al., 2015, 2013; Raghavan et al., 2012).
Our ﬁnding that potassium dichromate (VI) results in much more IL-18
production than chromium (III) chloride is in line with literature which
reports hexavalent chromium induced ROS production and NF-κB re-
lease from keratinocytes (Wang et al., 2010) and hexavalent chromium
acting as a pro-hapten and penetrating the skin where it is then reduced
enzymatically to trivalent chromium (Burrows, 1984). It is therefore
possible that our results can be explained by the inability of trivalent
chromium to penetrate the stratum corneum and activate TLRs. How-
ever, clearly the molecular pathways resulting in the generalized low
IL-18 production by metal salts and the signiﬁcance of this with respect
to sensitization needs further investigation.
Using traditional human diagnostic skin patch testing techniques,
the number of patients showing false negative reactions to metals is
suspected as being very high. To improve patch test diagnostics, the
correct label and classiﬁcation of diﬀerent metal salts needs to be de-
ﬁned so that optimal test panels can be selected. The outcome of the
traditional skin patch test is important in deciding the treatment regime
and whether or not the implant requires removal. Since skin patch
testing is accompanied with the risk of sensitizing the individual,
physiologically relevant human in vitro methods are preferred for
identifying relevant metal salts for use in improved diagnostics. Here
we show that the RhE IL-18 assay can be used to determine metal salt
penetration and (irritant) potency and therefore identify metal salts
suitable for patch testing. Since we could not label salts which may give
a positive patch test due to insuﬃcient IL-18 release, a combined test
with e.g. a dendritic cell maturation assay (with CXCL8 secretion as
readout) may be considered (Rachmawati et al., 2015; Toebak et al.,
2006). Previously we have shown that sodium tetrachloropalladate is a
superior diagnostic salt for use in patch testing compared to palladium
chloride (Muris et al., 2012). Using RhE we can now explain this ﬁnding
since we show that sodium tetrachloropalladate could penetrate the
stratum corneum, as indicated by an EC50 being obtained, whereas
palladium chloride cannot. We also show that gold (I) chloride readily
penetrates the stratum corneum whereas sodium aurothiosulphate (I)
does not in line with the absence of LLNA and human data for the later,
and neither salts were able to increase IL-18 production. However, it
has been described that gold (I) needs to be oxidized to gold (III) to
become antigenic and therefore a gold (III) salt may be preferred for
patch testing in the future (Schuhmann et al., 1990; Goebel et al.,
1995). Notably, none of the 4 tested titanium salts resulted in a de-
crease in metabolic activity of RhE indicating that these salts do not
penetrate the stratum corneum and therefore are not optimal salts for
diagnostic patch testing of suspected titanium allergy.
In summary, we have expanded on the panel of chemicals which
have been tested with the RhE IL-18 assay. We clearly show that metal
salts fall outside of the applicability domain of the assay due to in-
suﬃcient amounts of IL-18 being released and low cytotoxicity. The
reason for this is currently unknown, however, it is important to re-
member that only chemical-inducing type IV hypersensitivity reactions
(i.e. allergic contact dermatitis) will be positive in the RhE IL-18 assay.
Therefore, it should not be surprising if metals inducing primarily hu-
moral immune responses will be negative. With regards to chemical
potency testing, metal salts, with the exception of potassium dichro-
mate (VI) and mercuric (II) chloride all scored as moderate/weak sen-
sitizers. Since for a number of these metals this prediction was lower
than expected, it may reﬂect the poor ability of the metal salts to pe-
netrate the stratum corneum. Notably, all metal salts, for which no in
vivo data was available, scored as weak sensitizers in the RhE IL-18
assay.
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